Research ExplorerPublicationsPREFERE-Studie im Aufwind

PREFERE-Studie im Aufwind

Standard

PREFERE-Studie im Aufwind. / Ohlmann, Carsten-H; Stöckle, Michael; Albers, Peter; Schmidberger, Heinz; Härter, Martin; Kristiansen, Glen; Martus, Peter; Wellek, Stefan; Bussar-Maatz, Roswitha; Wiegel, Thomas.

In: UROLOGE, Vol. 55, No. 3, 03.2016, p. 313-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ohlmann, C-H, Stöckle, M, Albers, P, Schmidberger, H, Härter, M, Kristiansen, G, Martus, P, Wellek, S, Bussar-Maatz, R & Wiegel, T 2016, 'PREFERE-Studie im Aufwind', UROLOGE, vol. 55, no. 3, pp. 313-7. https://doi.org/10.1007/s00120-016-0047-z

APA

Ohlmann, C-H., Stöckle, M., Albers, P., Schmidberger, H., Härter, M., Kristiansen, G., Martus, P., Wellek, S., Bussar-Maatz, R., & Wiegel, T. (2016). PREFERE-Studie im Aufwind. UROLOGE, 55(3), 313-7. https://doi.org/10.1007/s00120-016-0047-z

Vancouver

Ohlmann C-H, Stöckle M, Albers P, Schmidberger H, Härter M, Kristiansen G et al. PREFERE-Studie im Aufwind. UROLOGE. 2016 Mar;55(3):313-7. https://doi.org/10.1007/s00120-016-0047-z

Bibtex

@article{f78d3e6829384c189cdc61a2e9c0887c,
title = "PREFERE-Studie im Aufwind",
abstract = "The PREFERE study, which compares the treatment options for prostate cancer with low and early intermediate risk, has recorded a noticeable upswing in recruitment since mid-2015. Responsible for this are the revised inclusion criteria and the wide support for this study in Germany. The inclusion criteria opened the study to the use of imaging techniques (MRI, C‑Trus / Anna) and the inclusion of all Gleason 3 + 3 = 6 cancers, regardless of tumor extent. In addition, patients can now be included who, for example due to the size of the prostate or existing obstructive micturition disorders, had a contraindication to percutaneous radiotherapy or brachytherapy - these can now be randomized between active surveillance and radical prostatectomy. With the increased recruitment numbers, it seems realistic that the required milestones in recruiting will be achieved.",
keywords = "Comorbidity, Diagnostic Imaging, Evidence-Based Medicine, Germany, Humans, Internationality, Male, Patient Selection, Postoperative Complications, Prostatectomy, Prostatic Neoplasms, Radiation Injuries, Radiotherapy, Survival Rate, Treatment Outcome, Journal Article, Multicenter Study, Randomized Controlled Trial",
author = "Carsten-H Ohlmann and Michael St{\"o}ckle and Peter Albers and Heinz Schmidberger and Martin H{\"a}rter and Glen Kristiansen and Peter Martus and Stefan Wellek and Roswitha Bussar-Maatz and Thomas Wiegel",
year = "2016",
month = mar,
doi = "10.1007/s00120-016-0047-z",
language = "Deutsch",
volume = "55",
pages = "313--7",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - PREFERE-Studie im Aufwind

AU - Ohlmann, Carsten-H

AU - Stöckle, Michael

AU - Albers, Peter

AU - Schmidberger, Heinz

AU - Härter, Martin

AU - Kristiansen, Glen

AU - Martus, Peter

AU - Wellek, Stefan

AU - Bussar-Maatz, Roswitha

AU - Wiegel, Thomas

PY - 2016/3

Y1 - 2016/3

N2 - The PREFERE study, which compares the treatment options for prostate cancer with low and early intermediate risk, has recorded a noticeable upswing in recruitment since mid-2015. Responsible for this are the revised inclusion criteria and the wide support for this study in Germany. The inclusion criteria opened the study to the use of imaging techniques (MRI, C‑Trus / Anna) and the inclusion of all Gleason 3 + 3 = 6 cancers, regardless of tumor extent. In addition, patients can now be included who, for example due to the size of the prostate or existing obstructive micturition disorders, had a contraindication to percutaneous radiotherapy or brachytherapy - these can now be randomized between active surveillance and radical prostatectomy. With the increased recruitment numbers, it seems realistic that the required milestones in recruiting will be achieved.

AB - The PREFERE study, which compares the treatment options for prostate cancer with low and early intermediate risk, has recorded a noticeable upswing in recruitment since mid-2015. Responsible for this are the revised inclusion criteria and the wide support for this study in Germany. The inclusion criteria opened the study to the use of imaging techniques (MRI, C‑Trus / Anna) and the inclusion of all Gleason 3 + 3 = 6 cancers, regardless of tumor extent. In addition, patients can now be included who, for example due to the size of the prostate or existing obstructive micturition disorders, had a contraindication to percutaneous radiotherapy or brachytherapy - these can now be randomized between active surveillance and radical prostatectomy. With the increased recruitment numbers, it seems realistic that the required milestones in recruiting will be achieved.

KW - Comorbidity

KW - Diagnostic Imaging

KW - Evidence-Based Medicine

KW - Germany

KW - Humans

KW - Internationality

KW - Male

KW - Patient Selection

KW - Postoperative Complications

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Radiation Injuries

KW - Radiotherapy

KW - Survival Rate

KW - Treatment Outcome

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

U2 - 10.1007/s00120-016-0047-z

DO - 10.1007/s00120-016-0047-z

M3 - SCORING: Zeitschriftenaufsatz

C2 - 26908120

VL - 55

SP - 313

EP - 317

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 3

ER -